CN104039349A - 用于治疗过敏反应的药物组合物 - Google Patents

用于治疗过敏反应的药物组合物 Download PDF

Info

Publication number
CN104039349A
CN104039349A CN201280057730.4A CN201280057730A CN104039349A CN 104039349 A CN104039349 A CN 104039349A CN 201280057730 A CN201280057730 A CN 201280057730A CN 104039349 A CN104039349 A CN 104039349A
Authority
CN
China
Prior art keywords
inhibitor
compositions
cells
mouse
allergen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280057730.4A
Other languages
English (en)
Chinese (zh)
Inventor
T.格伦瓦尔德
C.B.施密特-韦伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Munich Helmholtz Environment And Health Research Center Co Ltd
Pls Designs Co Ltd
Original Assignee
Munich Helmholtz Environment And Health Research Center Co Ltd
Pls Designs Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Munich Helmholtz Environment And Health Research Center Co Ltd, Pls Designs Co Ltd filed Critical Munich Helmholtz Environment And Health Research Center Co Ltd
Publication of CN104039349A publication Critical patent/CN104039349A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280057730.4A 2011-11-23 2012-11-23 用于治疗过敏反应的药物组合物 Pending CN104039349A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11075261.5 2011-11-23
EP11075261.5A EP2596802A1 (en) 2011-11-23 2011-11-23 Pharmaceutical composition for treatment of allergic reactions
PCT/EP2012/004884 WO2013075846A1 (en) 2011-11-23 2012-11-23 Pharmaceutical composition for treatment of allergic reactions

Publications (1)

Publication Number Publication Date
CN104039349A true CN104039349A (zh) 2014-09-10

Family

ID=47358079

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280057730.4A Pending CN104039349A (zh) 2011-11-23 2012-11-23 用于治疗过敏反应的药物组合物

Country Status (6)

Country Link
US (2) US20140335162A1 (enExample)
EP (1) EP2596802A1 (enExample)
CN (1) CN104039349A (enExample)
BR (1) BR112014012277A2 (enExample)
IN (1) IN2014DN03429A (enExample)
WO (1) WO2013075846A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105727371A (zh) * 2016-01-25 2016-07-06 北京天助畅运医疗技术股份有限公司 腹壁疝修补材料
CN116869964A (zh) * 2014-12-24 2023-10-13 耐克西缪恩有限公司 用于免疫疗法的纳米颗粒组合物和方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2813242A1 (en) * 2013-06-13 2014-12-17 PLS-Design GmbH Low molecular weight immune-modulators as adjuvants for specific immunotherapy
EP2918262B1 (en) * 2014-03-10 2023-08-09 PLS-Design GmbH Induction of antigen-specific tolerance by peripheral phagocytosis
PL3448391T3 (pl) 2016-04-27 2024-09-16 AbbVie Manufacturing Management Unlimited Company Sposoby leczenia chorób, w których jest szkodliwa aktywność il-13, przy zastosowaniu przeciwciała anty-il-13
CN107669638B (zh) * 2017-10-23 2020-05-22 华南理工大学 一种peg-pcl-peg三嵌段共聚物修饰的羟基积雪草苷脂质体及其应用
JP2023522676A (ja) * 2020-04-22 2023-05-31 キンドレッド バイオサイエンシズ インコーポレイテッド 動物用のｉｌ４／ｉｌ１３受容体分子

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1299272A (zh) * 1998-03-02 2001-06-13 应用疫苗技术公司 调节免疫应答的方法及装置
WO2010086312A1 (en) * 2009-01-28 2010-08-05 Novartis Ag Galenic formulations of organic compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5126147A (en) * 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
DE4137333A1 (de) 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
HUP9902824A3 (en) 1996-06-14 2001-11-28 Bayer Corp Pittsburgh T-cell selective interleukin-4 agonists
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
AR015175A1 (es) 1997-10-03 2001-04-18 Macromed Inc COMPOSICIoN ACUOSA BIODEGRADABLE POLIMÉRICA PARA LA ENTREGA DE UN FÁRMACO.
WO1999044583A2 (en) * 1998-03-02 1999-09-10 Applied Vaccine Technologies Corp. Methods and devices for modulating the immune response
US6841617B2 (en) * 2000-09-28 2005-01-11 Battelle Memorial Institute Thermogelling biodegradable aqueous polymer solution
US6451346B1 (en) * 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
US20010031262A1 (en) * 1999-12-06 2001-10-18 Michael Caplan Controlled delivery of antigens
ES2382891T3 (es) 2000-05-26 2012-06-14 Immunex Corporation Uso de anticuerpos IL-4R y sus composiciones
US20020076409A1 (en) 2000-07-12 2002-06-20 March Carl J. Method for treating cancer
US20030003074A1 (en) 2001-06-14 2003-01-02 Macromed, Inc. Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
ATE378427T1 (de) 2005-10-17 2007-11-15 Rina Netzwerk Rna Technologien Verfahren zur bestimmung einer unbekannten pns seqenz und seine verwendungen
US7947648B2 (en) * 2006-01-11 2011-05-24 Aerovance, Inc. Methods for treating asthma in human and non human primates using IL-4 mutant compositions
MX350501B (es) * 2007-10-12 2017-09-07 Massachusetts Inst Technology Nanotecnologia de vacuna.
EP2604628A3 (en) 2007-12-21 2013-08-21 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4R) - 173
JP5656370B2 (ja) 2009-07-01 2015-01-21 キヤノン株式会社 画像処理装置、画像処理システム、画像処理方法、およびプログラム

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1299272A (zh) * 1998-03-02 2001-06-13 应用疫苗技术公司 调节免疫应答的方法及装置
WO2010086312A1 (en) * 2009-01-28 2010-08-05 Novartis Ag Galenic formulations of organic compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUSANNE M. GRUNEWALD ET AL.: "An Antagonistic IL-4 Mutant Prevents Type I Allergy in the Mouse: Inhibition of the IL-4/IL-13 Receptor System Completely Abrogates Humoral Immune Response to Allergen and Development of Allergic Symptoms In Vivo", 《 THE JOURNAL OF IMMUNOLOGY》, vol. 160, no. 8, 15 April 1998 (1998-04-15), XP002102659 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116869964A (zh) * 2014-12-24 2023-10-13 耐克西缪恩有限公司 用于免疫疗法的纳米颗粒组合物和方法
CN116869964B (zh) * 2014-12-24 2024-10-18 耐克西缪恩有限公司 用于免疫疗法的纳米颗粒组合物和方法
CN105727371A (zh) * 2016-01-25 2016-07-06 北京天助畅运医疗技术股份有限公司 腹壁疝修补材料
CN105727371B (zh) * 2016-01-25 2019-04-09 北京天助畅运医疗技术股份有限公司 腹壁疝修补材料

Also Published As

Publication number Publication date
US20140335162A1 (en) 2014-11-13
US20180117143A1 (en) 2018-05-03
EP2596802A1 (en) 2013-05-29
WO2013075846A1 (en) 2013-05-30
BR112014012277A2 (pt) 2019-09-24
IN2014DN03429A (enExample) 2015-06-05

Similar Documents

Publication Publication Date Title
JP7586863B2 (ja) 共有ポリマー抗原コンジュゲート化粒子
US20180117143A1 (en) Pharmaceutical composition for treatment of allergic reactions
Jarvi et al. Immunogenicity challenges associated with subcutaneous delivery of therapeutic proteins
JP7007335B2 (ja) ペプチドコンジュゲート粒子
US20220273778A1 (en) Method of inducing antigen-specific tolerance in a subject by administering a composition comprising an apoptotic body surrogate and coupled immunodominant antigenic epitopes associated with autoimmune disease
JP6557140B2 (ja) ペプチドコンジュゲート粒子
JP2022101576A (ja) スギ花粉エピトープを封入するｔｉｍｐ（組織性メタロプロテアーゼ阻害因子）
KR20110117684A (ko) 항원-특이적 내성의 유도를 위한 조성물 및 방법
JP2012500855A (ja) Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
WO2007103048A2 (en) Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
WO2007024026A1 (ja) Ｔ細胞認識エピトープペプチドを固定化又は内包化した生分解性ナノ粒子
CA2929637C (en) USE OF IL-22 DIMERS IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF PANCREATITIS
WO2007080977A1 (ja) 免疫疾患の予防ないし治療剤および方法
US20130337045A1 (en) Controlled activation of complement components for use as endogenous adjuvant
JP2005528373A (ja) 免疫プロトコルにＦｌｔ３リガンドを用いる方法
US12109271B2 (en) Microparticle systems and their use for the treatment of multiple sclerosis
JP5836968B2 (ja) ＩｇＥ媒介性疾患の処置方法
ZA200400442B (en) Use of il 18 inhibitors in hypersensitivity disorders
NL2031833B1 (en) Immunotherapeutic compositions and adjuvants
EP2674168A1 (en) Modulation of effector T cell responses by local depletion of complement component C3
JP2025506717A (ja) 腫瘍内注射酵母ワクチン
US20050287152A1 (en) Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
Smarr Efficacy and Mechanisms of Cellular and Synthetic Antigen Carriers for the Pre-and Post-Sensitization Inhibition of Allergic Airway Inflammation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
AD01 Patent right deemed abandoned

Effective date of abandoning: 20170908